Cargando…

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy

The anti-tumor effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms which depends both on the type of virus and the route of delivery. Here, we show that intra-tumoral (i.t.) oncolysis by Reovirus induced the priming of a CD8+, Th1-type anti-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ilett, Elizabeth, Kottke, Timothy, Thompson, Jill, Rajani, Karishma, Zaidi, Shane, Evgin, Laura, Coffey, Matt, Ralph, Christy, Diaz, Rosa, Pandha, Hardev, Harrington, Kevin, Selby, Peter, Bram, Richard, Melcher, Alan, Vile, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387692/ https://www.ncbi.nlm.nih.gov/pubmed/27779616 http://dx.doi.org/10.1038/gt.2016.70

Ejemplares similares

Immunogenicity of self tumor associated proteins is enhanced through protein truncation
por: Kottke, Tim, et al.
Publicado: (2016)

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming
por: Steele, Lynette, et al.
Publicado: (2011)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Broad Antigenic Coverage Induced by Viral cDNA Library-based Vaccination Cures Established Tumors
por: Kottke, Timothy, et al.
Publicado: (2011)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
por: Huff, Amanda L., et al.
Publicado: (2018)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
por: Evgin, Laura, et al.
Publicado: (2021)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion
por: Cockle, Julia V., et al.
Publicado: (2017)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
por: Driscoll, Christopher B., et al.
Publicado: (2020)

Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming
por: Merrick, A, et al.
Publicado: (2005)

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
por: Jennings, Victoria A., et al.
Publicado: (2019)

Reovirus-Mediated Cytotoxicity and Enhancement of Innate Immune Responses Against Acute Myeloid Leukemia
por: Hall, Kathryn, et al.
Publicado: (2012)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Oncolytic virus-derived type I interferon restricts CAR T cell therapy
por: Evgin, Laura, et al.
Publicado: (2020)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Measles virus causes immunogenic cell death in human melanoma
por: Donnelly, Oliver G, et al.
Publicado: (2011)

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy
por: Vile, Richard, et al.
Publicado: (2023)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Oncolytic viruses: Narcissistic or altruistic arsonists?
por: Kendall, Luke, et al.
Publicado: (2023)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
por: Rajani, Karishma R., et al.
Publicado: (2015)

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer
por: Mansfield, D C, et al.
Publicado: (2016)

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism
por: McLaughlin, Martin, et al.
Publicado: (2020)

Applications of coxsackievirus A21 in oncology
por: Bradley, Stephen, et al.
Publicado: (2014)

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
por: Parrish, C, et al.
Publicado: (2015)

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
por: Schuelke, Matthew R., et al.
Publicado: (2019)

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
por: Müller, Louise M. E., et al.
Publicado: (2019)

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
por: McGray, A. J. Robert, et al.
Publicado: (2019)

Differential effects of Paclitaxel on dendritic cell function
por: John, Justin, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_in3e8tkst0m6b38gkb12mtegml